戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 processes could be inhibited by probucol and L-thyroxine.
2 f vasopressin and either triiodothyronine or L-thyroxine.
3 f vasopressin and either triiodothyronine or l-thyroxine.
4 s 41% for antithyroid medication and 13% for L-thyroxine.
5  normal range, 100-200 ng/dL [1.54-3.08 pmol/L]), thyroxine (1.35 mug/dL [17.37 nmol/L]; normal range
6  normal range, 100-200 ng/dL [1.54-3.08 pmol/L]), thyroxine (1.35 ug/dL [17.37 nmol/L]; normal range,
7 15.1-157.5 mug L(-1)) was more abundant than L-thyroxine (47.9-193.6 mug L(-1)), and reversed triiodo
8 consists of thyroid replacement therapy with l-thyroxine, adjusting the daily dose to the individual
9 ids alone and steroids plus triiodothyronine/l-thyroxine also significantly reduced prolonged graft d
10 notube recognition complexes for riboflavin, L-thyroxine and oestradiol.
11 ata on the adverse effects of broader use of L-thyroxine are sparse.
12               This approach was tested using L-thyroxine as a model analyte.
13 ive stable isotopic thyroid hormone (13)C(6)-L-thyroxine as the label of which the binding to rTTR is
14 ith SCH and high symptom burden at baseline, L-thyroxine did not improve hypothyroid symptoms or tire
15                                              L-thyroxine does not improve hypothyroid symptoms among
16 ia by solid phase synthesis with immobilised L-thyroxine, glucosamine, fumonisin B2 or biotin as temp
17 ols (CTL) and hypothyroid rats replaced with L-thyroxine (HT+T).
18 , including the chiral forms D-thyroxine and L-thyroxine in human milk.
19                                         Oral L-thyroxine is the treatment of choice because of its we
20                                              L-thyroxine (L-T4) malabsorption is a potential concern
21                                              L-thyroxine (L-T4) monotherapy is the standard treatment
22  with IC(50) values of 18-30 microM included L-thyroxine (L-T4), D-thyroxine (D-T4), 3,3', 5,5'-tetra
23 trol retinol-binding protein, vitamin A, and L-thyroxine levels in plasma and have the potential to m
24 e improved similarly between those receiving L-thyroxine (mean within-group change, -12.3 [95% CI, -1
25 es were also similar between those receiving L-thyroxine (mean within-group change, -8.9 [CI, -14.5 t
26  suggests mechanisms for the inadequacies of l-thyroxine monotherapy and highlights the possible role
27                                  Thereafter, l-thyroxine monotherapy at doses to normalize the serum
28     The last sentence of the section titled "L-Thyroxine Monotherapy Fails to Restore All Markers of
29 s has brought into question the inability of l-thyroxine monotherapy to universally normalize serum T
30 sion provided a physiologic means to justify l-thyroxine monotherapy, obviating concerns about incons
31 les, retinol-binding protein, vitamin A, and L-thyroxine, notably influenced transthyretin amyloidoge
32                                              L-thyroxine or matching placebo with mock dose titration
33 roidism that must be treated with aggressive L-thyroxine replacement and other supportive measures in
34 ter, after euthyroidism had been attained by L-thyroxine replacement therapy.
35  The applied therapy, combined with adequate L-thyroxine substitution, as well as vitamin D and selen
36 clear thyroid hormone receptor TRbeta1 (TR), L-thyroxine (T(4)) causes activation and nuclear translo
37                                              L-Thyroxine (T(4)) nongenomically promotes association o
38 ensitive method for the analysis of six THs, l-thyroxine (T(4)), 3,3',5-triiodo-l-thyronine (T(3)), 3
39                  Activated nongenomically by l-thyroxine (T(4)), mitogen-activated protein kinase (MA
40        HeLa and CV-1 cells treated only with L-thyroxine (T4) demonstrated increased tyrosine phospho
41                          The displacement of l-thyroxine (T4) from binding sites on transthyretin (TT
42 rum 3,5,3'-triiodothyronine (T3) with normal l-thyroxine (T4) levels, is associated with malignancy.
43 t evidence suggests that the thyroid hormone L-thyroxine (T4) stimulates growth of cancer cells via a
44 hyperthyroidism was generated by addition of L-thyroxine (T4) to drinking water.
45  of the label by the natural thyroid hormone l-thyroxine (T4), as a model analyte, is demonstrated in
46                Rats received placebo, 3.3-mg l-thyroxine (T4), or 20-mg T4 pellets (60-day release fo
47 Sprague-Dawley rats were injected daily with L-thyroxine (T4, 0.2 mg/kg s.c.).
48 sting vessels was increased 3-fold by either l-thyroxine (T4; 10(-7) mol/L) or 3,5,3'-triiodo-l-thyro
49 a membrane receptor, binds thyroid hormones (L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is
50  currently reads "... for steady delivery of L-thyroxine").This has been corrected in the online vers
51 benzo-p-dioxins and furans, with THs [total (L)-thyroxine (TT(4)), total 3,3',5-triiodo-(L)-thyronine
52 e or Tiredness score modified the effects of L-thyroxine versus placebo (P for interaction = 0.20 and